Literature DB >> 28947132

Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.

Michaël H Meel1, A Charlotte P Sewing2, Piotr Waranecki3, Dennis S Metselaar4, Laurine E Wedekind5, Jan Koster6, Dannis G van Vuurden7, Gertjan J L Kaspers8, Esther Hulleman9.   

Abstract

Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of brainstem cancer occurring mainly in children, for which there currently is no effective therapy. Current efforts to develop novel therapeutics for this tumor make use of primary cultures of DIPG cells, maintained either as adherent monolayer in serum containing medium, or as neurospheres in serum-free medium. In this manuscript, we demonstrate that the response of DIPG cells to targeted therapies in vitro is mainly determined by the culture conditions. We show that particular culture conditions induce the activation of different receptor tyrosine kinases and signal transduction pathways, as well as major changes in gene expression profiles of DIPG cells in culture. These differences correlate strongly with the observed discrepancies in response to targeted therapies of DIPG cells cultured as either adherent monolayers or neurospheres. With this research, we provide an argument for the concurrent use of both culture conditions to avoid false positive and false negative results due to the chosen method.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brainstem tumor; Cell culture; Kinase inhibitor; Neurosphere; Signal transduction; Targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28947132     DOI: 10.1016/j.yexcr.2017.09.032

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.

Authors:  Esther P Jane; Daniel R Premkumar; Swetha Thambireddy; Brian Golbourn; Sameer Agnihotri; Kelsey C Bertrand; Stephen C Mack; Max I Myers; Ansuman Chattopadhyay; D Lansing Taylor; Mark E Schurdak; Andrew M Stern; Ian F Pollack
Journal:  Mol Cancer Res       Date:  2020-04-01       Impact factor: 5.852

2.  Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.

Authors:  Emmanuel de Billy; Marsha Pellegrino; Domenico Orlando; Giulia Pericoli; Roberta Ferretti; Pietro Businaro; Maria Antonietta Ajmone-Cat; Sabrina Rossi; Lucia Lisa Petrilli; Nicola Maestro; Francesca Diomedi-Camassei; Marco Pezzullo; Cristiano De Stefanis; Paola Bencivenga; Alessia Palma; Rossella Rota; Francesca Del Bufalo; Luca Massimi; Gerrit Weber; Chris Jones; Andrea Carai; Simona Caruso; Biagio De Angelis; Ignazio Caruana; Concetta Quintarelli; Angela Mastronuzzi; Franco Locatelli; Maria Vinci
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

3.  Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.

Authors:  Maria Wiese; Feda H Hamdan; Klaudia Kubiak; Christopher Diederichs; Gerrit H Gielen; Gunther Nussbaumer; Angel M Carcaboso; Esther Hulleman; Steven A Johnsen; Christof M Kramm
Journal:  Cell Death Dis       Date:  2020-08-21       Impact factor: 8.469

4.  Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity.

Authors:  Anne-Florence Blandin; Aurélie Durand; Marie Litzler; Aurélien Tripp; Éric Guérin; Elisa Ruhland; Adeline Obrecht; Céline Keime; Quentin Fuchs; Damien Reita; Benoit Lhermitte; Andres Coca; Chris Jones; Isabelle Lelong Rebel; Pascal Villa; Izzie Jacques Namer; Monique Dontenwill; Dominique Guenot; Natacha Entz-Werle
Journal:  Cancers (Basel)       Date:  2019-11-26       Impact factor: 6.639

5.  Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.

Authors:  Dennis S Metselaar; Michaël H Meel; Bente Benedict; Piotr Waranecki; Jan Koster; Gertjan J L Kaspers; Esther Hulleman
Journal:  EBioMedicine       Date:  2019-11-14       Impact factor: 8.143

6.  Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.

Authors:  Jay F Sarthy; Michael P Meers; Derek H Janssens; Jorja G Henikoff; Heather Feldman; Patrick J Paddison; Christina M Lockwood; Nicholas A Vitanza; James M Olson; Kami Ahmad; Steven Henikoff
Journal:  Elife       Date:  2020-09-09       Impact factor: 8.140

Review 7.  Diffuse intrinsic pontine glioma: current insights and future directions.

Authors:  Dilakshan Srikanthan; Michael S Taccone; Randy Van Ommeren; Joji Ishida; Stacey L Krumholtz; James T Rutka
Journal:  Chin Neurosurg J       Date:  2021-01-11

Review 8.  Signaling pathways and mesenchymal transition in pediatric high-grade glioma.

Authors:  Michaël H Meel; Sophie A Schaper; Gertjan J L Kaspers; Esther Hulleman
Journal:  Cell Mol Life Sci       Date:  2017-11-21       Impact factor: 9.261

9.  MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.

Authors:  Michaël H Meel; Miriam Guillén Navarro; Mark C de Gooijer; Dennis S Metselaar; Piotr Waranecki; Marjolein Breur; Tonny Lagerweij; Laurine E Wedekind; Jan Koster; Marianne D van de Wetering; Netteke Schouten-van Meeteren; Eleonora Aronica; Olaf van Tellingen; Marianna Bugiani; Timothy N Phoenix; Gertjan J L Kaspers; Esther Hulleman
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

Review 10.  Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.

Authors:  Elisha Hayden; Holly Holliday; Rebecca Lehmann; Aaminah Khan; Maria Tsoli; Benjamin S Rayner; David S Ziegler
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.